Neurosense Therapeutics Ltd Stock Today
| NRSNW Stock | USD 0.22 0.01 4.76% |
PerformanceInsignificant
| Odds Of DistressVery High
|
NeuroSense Therapeutics is selling for under 0.22 as of the 23rd of March 2025; that is 4.76 percent up since the beginning of the trading day. The stock's lowest day price was 0.19. NeuroSense Therapeutics has a very high chance of experiencing financial distress in the next few years of operation. It also did not have a very good performance during the last 90 trading days. The performance scores are derived for the period starting the 23rd of December 2024 and ending today, the 23rd of March 2025. Click here to learn more.
NeuroSense Therapeutics Ltd., a clinical-stage biotechnology company, focuses on discovering and developing treatments for debilitating neurodegenerative diseases in Israel. NeuroSense Therapeutics Ltd. was incorporated in 2017 and is headquartered in Herzliya, Israel. More on NeuroSense Therapeutics Ltd
Moving against NeuroSense Stock
Follow Valuation Odds of Bankruptcy
Check how we calculate scores
NeuroSense Stock Highlights
| Business Concentration | Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors) |
NeuroSense Therapeutics Ltd (NRSNW) is traded on NASDAQ Exchange in USA. It is located in Building B, Herzliya, Israel, 4672562 and employs 18 people. NeuroSense Therapeutics is listed under Biotechnology category by Fama And French industry classification. The company classifies itself under Biotechnology sector and is part of Health Care industry.
NeuroSense Therapeutics Ltd has accumulated about 994 K in cash with (8.45 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.13.
Check NeuroSense Therapeutics Probability Of Bankruptcy
NeuroSense Therapeutics Risk Profiles
Investors will always prefer to have the highest possible return on investment while minimizing volatility. NeuroSense Therapeutics market risk premium is the additional return an investor will receive from holding NeuroSense Therapeutics long position in a well-diversified portfolio.
| Risk Adjusted Performance | 0.0461 | |||
| Jensen Alpha | 0.9536 | |||
| Total Risk Alpha | 2.44 | |||
| Sortino Ratio | 0.0442 |
NeuroSense Stock Against Markets
NeuroSense Therapeutics Corporate Management
| Yael Barak | VP Compliance | Profile | |
| Ferenc Tracik | Chief Officer | Profile | |
| Or Eisenberg | Chief Officer | Profile | |
| Alon BenNoon | CEO CoFounder | Profile | |
| Hagit Binder | Chief Officer | Profile | |
| Oron DVM | Chief Officer | Profile | |
| Ferenc MD | Chief Officer | Profile |
Additional Tools for NeuroSense Stock Analysis
When running NeuroSense Therapeutics' price analysis, check to measure NeuroSense Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy NeuroSense Therapeutics is operating at the current time. Most of NeuroSense Therapeutics' value examination focuses on studying past and present price action to predict the probability of NeuroSense Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move NeuroSense Therapeutics' price. Additionally, you may evaluate how the addition of NeuroSense Therapeutics to your portfolios can decrease your overall portfolio volatility.